A series of pyrrole derivatives and their preparation method and therapeutic use
US-2024327423-A1 · Oct 3, 2024 · US
US10869873B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10869873-B2 |
| Application number | US-201615150293-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 9, 2016 |
| Priority date | Dec 6, 2011 |
| Publication date | Dec 22, 2020 |
| Grant date | Dec 22, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention provides a method for treating viral infections and coinfections through the use of inhibitory agents that prevent a unique viral structural protein motifs from binding to host proteins from the clathrin adaptor proteins family and subsequently preventing viral replication.
Opening claim text (preview).
The invention claimed is: 1. A method of inhibiting assembly or budding of Dengue virus, comprising contacting a host cell that is infected with Dengue virus with sunitinib or a pharmaceutically acceptable salt of sunitinib, wherein the sunitinib inhibits adaptor-associated kinase 1 (AAK1), thereby inhibiting assembly or budding of the Dengue virus. 2. The method of claim 1 , wherein said sunitinib or pharmaceutically acceptable salt of sunitinib blocks binding of a viral structural protein to a host protein. 3. The method of claim 1 , wherein said sunitinib or pharmaceutically acceptable salt of sunitinib competes with a viral structural protein for binding to a host protein. 4. The method of claim 1 , wherein said sunitinib or pharmaceutically acceptable salt of sunitinib competes with a host protein for binding to a viral structural protein. 5. The method of claim 1 , further comprising contacting said host cell with erlotinib, midostaurin, or a pharmaceutically acceptable salt or combination thereof. 6. The method of claim 5 , wherein the host cell is contacted with erlotinib or a pharmaceutically acceptable salt of erlotinib. 7. The method of claim 5 , wherein the host cell is contacted with midostaurin or a pharmaceutically acceptable salt of midostaurin. 8. The method of claim 1 , wherein assembly or budding of said Flaviviridae is inhibited.
involving cells · CPC title
having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine · CPC title
Indoles, e.g. pindolol · CPC title
Preparation of malt extract or of special kinds of malt, e.g. caramel, black malt (malt products for use as foodstuffs A23L) · CPC title
ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.